Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with limited disruptions, and institutions are increasing their positions in innovative companies, maintaining a positive outlook on undervalued innovative targets [1][4] - The overall market sentiment has improved, driven by significant business development transactions, and the pharmaceutical sector is expected to continue its steady growth in 2026, despite potential short-term volatility [4][5] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, ranking second among 12 industry indices [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - Since Q4 2025, the proportion of domestic capital holding pharmaceutical stocks through Hong Kong Stock Connect has slightly decreased, while foreign capital holdings have increased [32] - As of February 10, 2026, domestic holdings were at 22.2%, down 0.2 percentage points, while foreign holdings rose to 39.7%, up 0.9 percentage points [32] Sales Performance - In 2025, China's pharmaceutical market sales decreased by 1% year-on-year, with public hospitals accounting for the largest market share at 10,977 billion RMB, down 2.1% [5] - Retail pharmacy sales reached 5,878 billion RMB, growing by 2.4%, with online pharmacies seeing a significant increase of 13.6% [5] National Procurement - The recent national procurement round had a high selection rate of 93%, with 1,020 products from 1,091 participating companies expected to be implemented by the end of March 2026 [5] - The procurement process has seen increased participation and a diverse range of selected products, ensuring stability in clinical demand [5] Investment Recommendations - The report recommends focusing on innovative drugs, particularly companies like Sanofi and Hengrui Medicine, which have rich catalysts and clear long-term growth logic [4] - It also suggests looking into CXO companies benefiting from high downstream demand and improving financing conditions, such as WuXi AppTec [4]

Core Insights - Korean investors have shown significant interest in various stocks and ETFs in the Hong Kong Stock Exchange, with the top ten purchases reflecting a diverse investment strategy [1][3] Investment Highlights - The top purchase by Korean investors is MiniMax-WP, with an investment amount of 20.67 million USD [1][3] - The second highest is the 华夏沪深300ETF, attracting 19.18 million USD [1][3] - 澜起科技 follows closely with an investment of 18.65 million USD [1][3] - 安硕恒生科技ETF received 7.36 million USD from Korean investors [1][3] - 南方东英每日杠杆三星电子 saw an investment of 7.33 million USD [1][3] - 英诺赛科 attracted 4.17 million USD in purchases [1][3] - Premia中国科创50ETF received 3.38 million USD [1][3] - 药明合联 was purchased for 3.13 million USD [1][3] - 歌礼制药 saw investments totaling 2.45 million USD [1][3] - Global X中国半导体ETF attracted 2.07 million USD [1][3]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with a high selection rate of 93%, indicating a positive outlook for innovative companies in the sector [4][5] - The market sentiment has improved, driven by significant business development (BD) transactions, suggesting a continuation of the positive trend in 2026 despite potential short-term volatility [4] - The report emphasizes the importance of focusing on fundamentals and valuations when selecting stocks, particularly undervalued innovative companies that have been overlooked during market fluctuations [4] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, outperforming the broader market [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - As of February 10, 2026, domestic institutional holdings through Hong Kong Stock Connect slightly decreased to 22.2%, while foreign holdings increased to 39.7%, indicating a shift towards more positive sentiment among foreign investors [32] - Key increases in holdings were noted in leading CXO companies benefiting from demand recovery, such as Tigermed and WuXi AppTec [37][38] Valuation Overview - The report provides a valuation summary for various companies, with notable buy ratings for AstraZeneca, BeiGene, and others, indicating strong growth potential [3] - The average price-to-earnings (P/E) ratio for the healthcare sector is reported at 28.4 times, with specific segments like biopharmaceuticals at 13.1 times [16] Sales Trends - The report notes a 1% year-on-year decline in China's pharmaceutical market sales for 2025, with significant variations across different sales channels [5] - Public hospitals accounted for the largest market share but experienced a 2.1% decline, while retail pharmacies saw a 2.4% increase, driven by online sales growth [5] Procurement Insights - The recent national procurement round involved 316 commonly used drugs, with a high participation rate and diverse product offerings, ensuring stable clinical supply [5] - The procurement process has been refined to enhance quality and reliability, with stricter requirements for participating companies [5]

Core Viewpoint - Southbound capital flow into Hong Kong stocks showed a net inflow of approximately 45.67 billion HKD despite a generally weak market performance, indicating continued interest from investors [2][3]. Southbound Capital Flow - Today's southbound trading volume reached about 947.77 billion HKD, an increase of approximately 40 billion HKD from the previous day, accounting for 39.70% of the total turnover of the Hang Seng Index, which has fallen below 40% again [2]. - The net inflow from the Shanghai-Hong Kong Stock Connect was about 46.56 billion HKD, while the Shenzhen-Hong Kong Stock Connect experienced a net outflow of approximately 0.89 billion HKD [2]. Individual Stock Performance - Significant net purchases included Tencent Holdings (14.29 billion HKD), Xiaomi Group (10.20 billion HKD), Meituan (9.85 billion HKD), and Kingsoft Cloud (1.89 billion HKD) [3]. - Major net outflows were observed in WuXi Biologics (3.92 billion HKD), Zijin Mining (3.46 billion HKD), and Pop Mart (3.01 billion HKD) [3]. Investment Highlights - Tencent Holdings saw a decline of 2.28% with a net increase of 25.2 million shares over the past five days, indicating a short-term inflow trend [4]. - Xiaomi Group decreased by 1.56%, with a net increase of 53.81 million shares in the last five days, showing continued short-term inflow [4]. - Meituan dropped 4.50%, but there was a net increase of 20.59 million shares over the past five days, suggesting accelerated short-term inflow [4]. - Kingsoft Cloud increased by 7.82%, with a net increase of 35.20 million shares in the last five days, indicating sustained short-term inflow [4]. - WuXi Biologics fell by 0.14%, but there was a net increase of 25.83 million shares over the past five days, maintaining a primary inflow trend [4]. - Zijin Mining rose by 3.45%, with a net reduction of 8.28 million shares in the last five days, indicating a primary outflow trend [4]. - Pop Mart decreased by 1.10%, with a net increase of 5.58 million shares over the past five days, showing a slowdown in inflow [4]. Recent Trading Activity - In the past month, Tencent Holdings had a net capital inflow of 16.44 billion HKD, while Meituan experienced a net inflow of 6.70 billion HKD despite a 4.50% decline [5]. - Xiaomi Group recorded a net inflow of 7.34 billion HKD, while WuXi Biologics faced a net outflow of 3.92 billion HKD [5].

Investment Rating - The report maintains a target price of HKD 48.5 and rates the company as "Outperform" [1] Core Insights - WuXi Biologics (02269) has issued an earnings upgrade for the second half of 2025, with revenue expected to grow by 17% year-on-year, aligning with expectations, while net profit is projected to increase by 38% to RMB 2.6 billion [1] - Adjusted net profit is anticipated to rise by 31% to RMB 3.7 billion, significantly exceeding market expectations [1] - The gross profit margin is expected to increase by 6.2 percentage points to 48.8%, which is a key positive surprise in this earnings upgrade and the main driver behind the better-than-expected profit performance [1] - WuXi Biologics remains a preferred stock within the Chinese Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors [1]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.86% to 27,032.54 points, the Hang Seng Tech Index down by 1.65% to 5,408.98 points, and the National Enterprises Index decreasing by 1.00% to 9,175.18 points [1] - The Hang Seng Index opened lower at 27,210.56 points, fluctuated downwards, and closed down by 233.84 points, with a total trading volume exceeding 238.7 billion HKD [1] - The net inflow for the southbound trading (Hong Kong Stock Connect) was over 4.5 billion HKD [1] Sector Performance - Most sectors saw declines, with notable exceptions in metals, chips, high-speed rail infrastructure, and wind power, which experienced gains [1] - Sectors such as oil and gas, banking, brokerage, and coal showed mixed performance, while new consumption, gold, commercial aerospace, biomedicine, new energy vehicles, technology, and real estate mostly declined [1] Individual Stock Movements - Xiaomi Group decreased by 1.56%, while Zijin Mining increased by 3.45% [1] - SenseTime rose by 6.77%, and Ctrip Group fell by 3.90% [1] - WuXi Biologics dropped by 0.14%, Pop Mart fell by 1.10%, and SMIC decreased by 0.29% [1] - Notable gainers included Zhizhen Technology with a rise of 28.68%, and Longi Green Energy up by 5.56% [1] - China Construction Bank fell by 0.86%, while CATL increased by 4.14%, and Dongfang Electric surged by 12.38% [1] - Yao Cai Securities Financial dropped by 4.15%, and China Petroleum gained 0.85% [1] Top Traded Stocks - Tencent Holdings fell by 2.28% with a trading volume exceeding 21.2 billion HKD [2] - Alibaba decreased by 0.94% with a trading volume over 8.9 billion HKD [2] - Meituan dropped by 4.50% with a trading volume of 7.7 billion HKD [2]

Core Viewpoint - Bank of America Securities reports that WuXi Biologics has issued a positive earnings forecast, expecting a 16.7% year-on-year revenue growth to reach 21.8 billion yuan by 2025, aligning with the bank's expectations [1] Revenue and Growth - The revenue growth is attributed to a record number of new projects and an expansion of service offerings, particularly in the BsAb and ADC platforms [1] - The revenue forecast for 2025 to 2027 has been slightly increased by 1% [1] Profitability - Gross margin is expected to expand by 5 percentage points year-on-year to 46%, exceeding the bank's expectations due to improved capacity utilization and efficiency gains from the Lean Operations Management System (WBS) [1] - Net profit and attributable net profit are projected to be 5.7 billion and 4.9 billion yuan, respectively, reflecting year-on-year growth of 45.3% and 46.3% [1] - Net profit forecast has been raised by 7% to 12% [1] Target Price and Rating - The target price has been adjusted from 41.8 HKD to 47 HKD, while maintaining a "Neutral" rating [1]

Core Viewpoint - Bank of America Securities reports that WuXi Biologics has issued a positive earnings forecast, expecting a 16.7% year-on-year revenue growth to reach 21.8 billion yuan by 2025, aligning with the bank's expectations [1] Revenue and Growth - The revenue growth is attributed to a record number of new projects and an expansion of service offerings, particularly in the BsAb and ADC platforms [1] - The revenue forecast for 2025 to 2027 has been slightly increased by 1% [1] Profitability - Gross margin is expected to expand by 5 percentage points year-on-year to 46%, surpassing the bank's expectations due to improved capacity utilization and efficiency gains from the Lean Operations Management System (WBS) [1] - Net profit and net profit attributable to shareholders are projected to be 5.7 billion yuan and 4.9 billion yuan, respectively, reflecting year-on-year growth of 45.3% and 46.3% [1] - Net profit forecast has been raised by 7% [1] Target Price and Rating - The target price has been adjusted from 41.8 HKD to 47 HKD, while maintaining a "Neutral" rating [1]

Core Viewpoint - Nomura's report indicates that WuXi Biologics has announced a profit forecast, expecting a 16.7% year-on-year revenue growth to 21.8 billion yuan in 2025, slightly above the market expectation of 21.5 billion yuan [1] Revenue and Profit Forecast - The gross margin is expected to improve by 5 percentage points year-on-year to 46%, also exceeding the market expectation of 43% [1] - Net profit and profit attributable to shareholders are projected to grow by 45.3% and 46.3% year-on-year, reaching 5.7 billion yuan and 4.9 billion yuan, respectively, surpassing market expectations of 4.8 billion yuan and 4.4 billion yuan [1] - For the second half of 2025, revenue is estimated to grow by 17.2% year-on-year to 11.8 billion yuan, with profit growth of 38%, both exceeding market expectations [1] Management Insights - Management attributes the growth to optimistic performance in research service revenue and an increase in projects entering later stages due to enhanced service capabilities [1] Target Price Adjustment - Nomura has raised its target price from 37.36 HKD to 50.54 HKD, maintaining a "Buy" rating [1]

Market Overview - The Hong Kong stock market experienced a downward trend in the morning session, with the Hang Seng Index falling by 0.89% and the Hang Seng Tech Index declining by 1.68% [1] Sector Performance - The AI application sector showed strong performance, with notable gains: Zhiyun surged nearly 25%, MINIMAX-WP increased over 14%, and Kingsoft Cloud rose more than 4% [1] - The electric equipment sector continued its upward momentum, highlighted by Dongfang Electric rising over 11%, Harbin Electric increasing more than 7%, and Flat Glass Group gaining over 2% [1] - The optical communication sector was active, with Yangtze Optical Fiber and Cable rising over 11%, Huiju Technology increasing more than 7%, and Cambridge Technology gaining over 2% [1] - The pharmaceutical sector exhibited mixed results, with Reborn Bio rising by 13.65%, WuXi Biologics increasing by 4.83%, and Baidu's biotech unit rising by 3.88%, while three other companies saw declines [1] Capital Flow - Southbound capital saw a net inflow of nearly 2.8 billion HKD in the morning session [1]